Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2
S. B. Biering, E. Van Dis, E. Wehri, L. H. Yamashiro, X. Nguyenla, C. Dugast-Darzacq, T. G. Graham, J. R. Stroumza, G. R. Golovkine, A. W. Roberts, D. M. Fines, J. N. Spradlin, C. C. Ward, T. Bajaj, D. Dovala, , S. A. Stanley
This study screens FDA-approved compounds for antiviral activity against SARS-CoV-2 and identifies 13 effective compounds, including seven new candidates and one synergistic combination with remdesivir.
bioRxiv · Dec 30, 2020Microbiology